Have a feature idea you'd love to see implemented?
Let us know!

- Stocks
- Healthcare
- NASDAQ: INCY

Price (delayed)

$76.13

Market cap

$14.67B

P/E Ratio

447.82

Dividend/share

N/A

EPS

$0.17

Enterprise value

$13.39B

Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware. The company was founded in Palo Alto, California in 1991 and went public in 1993. Incyte has one drug,

Incyte's revenue has increased by 13% YoY and by 6% from the previous quarter

INCY's gross profit is up by 12% year-on-year and by 5% since the previous quarter

INCY's equity is down by 36% year-on-year but it is up by 6% since the previous quarter

INCY's net income has dropped by 92% year-on-year and by 67% since the previous quarter

INCY's EPS has shrunk by 91% YoY and by 55% QoQ

What are the main financial stats of INCY

Market
Valuations
Earnings

Shares outstanding

192.65M

Market cap

$14.67B

Enterprise value

$13.39B

Price to earnings (P/E)

447.82

Price to book (P/B)

4.62

Price to sales (P/S)

3.6

EV/EBIT

48.43

EV/EBITDA

36.71

EV/Sales

3.29

Revenue

$4.08B

EBIT

$276.53M

EBITDA

$364.8M

Free cash flow

$30.7M

Per share
Balance sheet
Liquidity

EPS

$0.17

Free cash flow per share

$0.16

Book value per share

$16.47

Revenue per share

$21.16

TBVPS

$24.59

Total assets

$5.01B

Total liabilities

$1.84B

Debt

$32.16M

Equity

$3.17B

Working capital

$1.31B

Debt to equity

0.01

Current ratio

1.87

Quick ratio

1.69

Net debt/EBITDA

-3.49

Margins
Efficiency
Dividend

EBITDA margin

9%

Gross margin

92.8%

Net margin

0.8%

Operating margin

-1.3%

Return on assets

0.6%

Return on equity

0.8%

Return on invested capital

13.3%

Return on capital employed

7.9%

Return on sales

6.8%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Incyte stock price performed over time

Intraday

2.71%

1 week

17%

1 month

11.86%

1 year

40.02%

YTD

21.25%

QTD

15.17%

How have Incyte's revenue and profit performed over time

Revenue

$4.08B

Gross profit

$3.78B

Operating income

-$52.88M

Net income

$32.48M

Gross margin

92.8%

Net margin

0.8%

Incyte's operating income has plunged by 111% YoY

INCY's operating margin has dropped by 109% year-on-year

The net margin has dropped by 93% year-on-year and by 68% since the previous quarter

INCY's net income has dropped by 92% year-on-year and by 67% since the previous quarter

What is Incyte's growth rate over time

What is Incyte stock price valuation

P/E

447.82

P/B

4.62

P/S

3.6

EV/EBIT

48.43

EV/EBITDA

36.71

EV/Sales

3.29

INCY's EPS has shrunk by 91% YoY and by 55% QoQ

INCY's equity is down by 36% year-on-year but it is up by 6% since the previous quarter

The stock's price to book (P/B) is 36% more than its last 4 quarters average of 3.4 but 9% less than its 5-year quarterly average of 5.1

INCY's P/S is 35% below its 5-year quarterly average of 5.5 but 6% above its last 4 quarters average of 3.4

Incyte's revenue has increased by 13% YoY and by 6% from the previous quarter

How efficient is Incyte business performance

The ROE has plunged by 91% YoY and by 62% from the previous quarter

INCY's return on assets has dropped by 91% year-on-year and by 63% since the previous quarter

The ROIC has plunged by 66% YoY and by 24% from the previous quarter

INCY's ROS has shrunk by 62% YoY and by 26% QoQ

What is INCY's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for INCY.

How did Incyte financials performed over time

Incyte's total assets is 172% more than its total liabilities

The company's quick ratio has shrunk by 54% YoY

The current ratio has plunged by 52% YoY and by 2.6% from the previous quarter

The debt is 99% smaller than the equity

INCY's equity is down by 36% year-on-year but it is up by 6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.